Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment.

SAR405838 is a potent and specific MDM2 inhibitor currently being evaluated in Phase I clinical trials for the treatment of human cancer. Using the SJSA-1 osteosarcoma cell line which harbors an amplified MDM2 gene and wild-type p53, we have investigated the acquired resistance mechanisms both in vitro and in vivo to SAR405838. Treatment of SJSA-1 cells with SAR405838 in vitro leads to dose-dependent cell growth inhibition, cell cycle arrest and robust apoptosis.

Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo.

Purpose: Two clinical-stage anticancer drugs, the Bcl-2 inhibitor ABT-263, and the MDM2 inhibitor SAR405838 achieve complete tumor regression in animal models of leukemia but also induce acquired resistance. Elucidation of acquired resistance mechanisms and development of strategies to overcome the resistance are critical for their successful clinical development.

Experimental Design: We employed RS4;11 and MV4;11 cell lines, two acute leukemia models, to investigate acquired resistance mechanisms for both drugs in vitro and in vivo and evaluated several treatment regimens in xenograft mouse models to improve long-term, complete tumor regression.

SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.

Blocking the oncoprotein murine double minute 2 (MDM2)-p53 protein-protein interaction has long been considered to offer a broad cancer therapeutic strategy, despite the potential risks of selecting tumors harboring p53 mutations that escape MDM2 control. In this study, we report a novel small-molecule inhibitor of the MDM2-p53 interaction, SAR405838 (MI-77301), that has been advanced into phase I clinical trials. SAR405838 binds to MDM2 with K(i) = 0.

Syntheses, structures, and photochemistry of manganese nitrosyls derived from designed Schiff base ligands: potential NO donors that can be activated by near-infrared light.

Two manganese nitrosyls, namely, [Mn(SBPy(3))(NO)](ClO(4))(2) (1) and [Mn(SBPy(2)Q)(NO)](ClO(4))(2) (2), have been synthesized by using designed pentadentate Schiff base ligands N,N-bis(2-pyridylmethyl)amine-N-ethyl-2-pyridine-2-aldimine (SBPy(3)) and N,N-bis(2-pyridyl methyl)amine-N-ethyl-2-quinoline-2-aldimine (SBPy(2)Q). Reaction of NO(g) with [Mn(SBPy(3))(MeOH)](ClO(4))(2) and [Mn(SBPy(2)Q)(EtOH)](ClO(4))(2) in MeCN affords 1 and 2, respectively, in good yields. Narrow-width peaks in the (1)H NMR spectra and strong nu(NO) at 1773 cm(-1) (of 1) and 1759 cm(-1) (of 2) confirm a strongly coupled {low-spin Mn(II)-NO*}formulation for both these {Mn-NO}(6) nitrosyls.

Formation of a triply bridged mu-oxo diiron(III) core stabilized by two deprotonated carboxamide groups upon photorelease of NO from a [Fe-NO]6 iron nitrosyl.

The iron nitrosyl [(PaPy2Q)Fe(NO)](ClO4)2 (2), derived from the quinoline-based ligand PaPy2QH (N,N-bis(2-pyridylmethyl)amine-N-ethyl-2-quinoline-2-carboxamide, where H is dissociable proton) has been characterized by spectroscopy and X-ray diffraction techniques. The 1H NMR spectrum (S = 0 ground state) and v(NO) value of 1885 cm(-1) indicate that 2 is a [Fe-NO]6 nitrosyl. Although 2 is stable in the dark, exposure of an acetonitrile solution of 2 (lambdamax = 510 nm) to light in the visible range causes rapid release of NO and formation of the solvato species [(PaPy2Q)Fe(MeCN)](ClO4)2 (6).